Cantitate/Preț
Produs
Total produse
Vezi coșul
Resistance to Tyrosine Kinase Inhibitors de Daniele Focosi

Resistance to Tyrosine Kinase Inhibitors: Resistance to Targeted Anti-Cancer Therapeutics

Editat de Daniele Focosi
en Limba Engleză Hardback – 14 noi 2016
The volume will serve as a primer on tyrosine kinase signaling and its importance in cancer. The volume will first introduce the common denominators of small-molecule and antibody-derived inhibitors, as well as the general phenomenon of resistance. The volume will then detail resistance to the most commonly used classes of tyrosine kinase inhibitors, and will focus specific chapters on resistance to BCR-ABL1, FLT3, angiokinase family members, and ALK inhibitors.
Citește tot Restrânge

Toate formatele și edițiile

Toate formatele și edițiile Preț Express
Paperback (1) 105786 lei  6-8 săpt.
  Springer International Publishing – 30 apr 2018 105786 lei  6-8 săpt.
Hardback (1) 106464 lei  6-8 săpt.
  Springer International Publishing – 14 noi 2016 106464 lei  6-8 săpt.

Din seria Resistance to Targeted Anti-Cancer Therapeutics

  • 5% Current Applications for Overcoming Resistance to Targeted Therapies
    Preț: 69754 lei
  • 5% Resistance to Proteasome Inhibitors in Cancer: Molecular Mechanisms and Strategies to Overcome Resistance
    Preț: 107543 lei
  • 5% Resistance to Targeted Therapies Against Adult Brain Cancers
    Preț: 106870 lei
  • 5% Molecular Mechanisms of Tumor Cell Resistance to Chemotherapy: Targeted Therapies to Reverse Resistance
    Preț: 106197 lei
  • 5% TRAIL, Fas Ligand, TNF and TLR3 in Cancer
    Preț: 107157 lei
  • 5% Resistance to Molecular Therapies for Hepatocellular Carcinoma
    Preț: 106248 lei
  • 5% Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways
    Preț: 106782 lei
  • 5% Resistance to Targeted Therapies in Breast Cancer
    Preț: 106464 lei
  • 5% Resistance of Targeted Therapies Excluding Antibodies for Lymphomas
    Preț: 81690 lei
  • 5% Resistance to Ibritumomab in Lymphoma
    Preț: 69542 lei
  • 5% Cancer Stem Cell Resistance to Targeted Therapy
    Preț: 69437 lei
  • 5% Resistance to Immunotherapeutic Antibodies in Cancer: Strategies to Overcome Resistance
    Preț: 106248 lei
  • 5% Resistance to Targeted Therapies in Lymphomas
    Preț: 69186 lei
  • 5% Resistance to Targeted Therapies in Multiple Myeloma
    Preț: 99519 lei
  • 5% Resistance to Targeted ABC Transporters in Cancer
    Preț: 70285 lei
  • 5% Resistance to Photodynamic Therapy in Cancer
    Preț: 70055 lei
  • 5% Resistance to Immunotoxins in Cancer Therapy
    Preț: 70055 lei
  • 5% Resistance of Cancer Cells to CTL-Mediated Immunotherapy
    Preț: 70586 lei
  • 5% Resistance to Aromatase Inhibitors in Breast Cancer
    Preț: 70250 lei
  • 5% Defects in T Cell Trafficking and Resistance to Cancer Immunotherapy
    Preț: 69718 lei

Preț: 106464 lei

Preț vechi: 112068 lei
-5% Nou

Puncte Express: 1597
Preț estimativ în valută:
20377€ • 21238$ • 16963£

Carte tipărită la comandă

Livrare economică 07-21 ianuarie 25

 Adaugă în coș

Wish list
Gift list
Am citit!
Adaugă în listă
Preluare comenzi: 021 569.72.76

Specificații

ISBN-13: 9783319460901
ISBN-10: 3319460900
Pagini: 334
Ilustrații: XIII, 188 p. 8 illus., 6 illus. in color.
Dimensiuni: 155 x 235 x 13 mm
Greutate: 0.46 kg
Ediția:1st ed. 2016
Editura: Springer International Publishing
Colecția Springer
Seria Resistance to Targeted Anti-Cancer Therapeutics

Locul publicării:Cham, Switzerland

Cuprins

Tyrosine Kinase Signaling Pathways in Normal and Cancer Cells.- Resistance to Tyrosine Kinase Inhibitors in different types of solid cancer.- The Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: An Overview.- Resistance to FLT3 Inhibitors.- Resistance to ALK inhibitors.- Resistance to Angiokinase Inhibitors.- Indications for Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors.

Notă biografică

Dr.Daniele Focosi was born in Lucca (Italy) in 1980. He graduated in Medicine with full grades in 2005 at the University of Pisa, and completed specialization in hematology in 2009. He achieved a Ph.D. degree in Clinical and Fundamental Virology in 2014, and a master degree in Clinical Trials in Oncology-Hematology in 2014.
He has authored 106 peer-reviewed manuscripts indexed on PubMed, for a total h-index of 16 and an overall impact factor of over 1400 points. He has been a fellow of the International Centre for Genetic Engineering and Biotechnology (ICGEB) in Trieste, and of the Collegio Ghislieri in Pavia, Italy. He is currently employed full-time at the Pisa University Hospital, where he is also a member of the Faculty of the PhD School in Clinical and Translational Sciences at University of Pisa.
He has given 37 oral and 47 poster presentations at international medical congresses, and is member of the editorial board of 17 peer-reviewed journals.He has received awards from the European Federation of Immunogenetics, the European Society for Organ Transplantation, the Italian Society for Hematology, the Italian Interregional Transplant Association, the Italian Bone Marrow Donor Association, the Italian Society for Experimental Hematology, the Italian Society against Leukemia/Lymphoma/Myeloma.

Textul de pe ultima copertă

The volume will serve as a primer on tyrosine kinase signaling and its importance in cancer. The volume will first introduce the common denominators of small-molecule and antibody-derived inhibitors, as well as the general phenomenon of resistance. The volume will then detail resistance to the most commonly used classes of tyrosine kinase inhibitors, and will focus specific chapters on resistance to BCR-ABL1, FLT3, angiokinase family members, and ALK inhibitors.

Caracteristici

The volume will provide readers with a primer on tyrosine kinase signaling and its importance in cancer The reader will be first introduced to common denominators of small-molecule and antibody-derived inhibitors, and with the general phenomemon of resistance Then specific reviews will focus on resistance to the most commonly used classes of tyrosine kinase inhibitors, namely BCR-ABL1, FLT3, the HER family members, angiokinase family members, ALK and the Raf/MEK/MAPK pathway Includes supplementary material: sn.pub/extras